Inst. Holders
50 funds
CNTA
Centessa Pharmaceuticals plc
—
12-mo target$40.25 (-0.6%)
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)30 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CNTA right now — valuation, ownership and activity at a glance.
Inst. Value
$3.0B
Inst. Activity
0 buys / 30 sells
Insider Activity
$0.00 buy / $0.00 sell
SEC Reports
5
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 10, 2026 earnings_calendar
Jul 6, 2026 SEC CNTA Q2 2026 Earnings Scheduled — 2026-08-10
Centessa Pharmaceuticals filed a Form 15-12G on July 6, 2026, to voluntarily deregister its ordinary shares and American
15-12G — Impact 7/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — EXIT
0 shares ($0.00)
Jun 24, 2026 Insider
Stuckley Carol disposed of 208,474 shares
Director
Jun 24, 2026 Insider
Weinhoff Gregory M disposed of 65,925 shares
Chief Business Officer
Jun 24, 2026 Insider
Apr 17, 2026 SEC HUSSAIN IQBAL J disposed of 221,559 shares
Chief Legal Officer
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as a Scheme of Arrangem
PREM14A — Impact 9/10
Analyst ratings buy % -50.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 20, 2026 | Wells Fargo | DOWNGRADE | Equal-Weight | 54% |
| Apr 2, 2026 | Guggenheim | DOWNGRADE | Neutral | 52% |
| Apr 1, 2026 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Mar 31, 2026 | Wolfe Research | DOWNGRADE | Peer Perform | 52% |
| Mar 31, 2026 | Needham | DOWNGRADE | Hold | 50% |
| Feb 24, 2026 | Wolfe Research | INITIATE | Outperform | 52% |
| Jan 29, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Jan 2, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Jan 2, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 5 | 10 | 0 | 0 | 47% | |
| Aug 1, 2026 | 4 | 5 | 10 | 0 | 0 | 47% | |
| Jul 1, 2026 | 4 | 5 | 10 | 0 | 0 | 47% | |
| Jun 1, 2026 | 4 | 5 | 10 | 0 | 0 | 47% | |
| May 1, 2026 | 4 | 5 | 10 | 0 | 0 | 47% | |
| Apr 1, 2026 | 6 | 8 | 5 | 0 | 0 | 74% | |
| Mar 1, 2026 | 8 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 13 | 1 | 0 | 0 | 95% |
Price targets
Where 4 covering analysts think CNTA trades over the next 12 months.
$40.25 -0.6% upside Hold
Current$40.50 Low$38.00 Median$39.00 High$45.00 4 analysts
$38.00$45.00
Analyst rating Hold· 2.6/5 as of Aug 24, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 2 bullish, 3 bearish, 0 mixed, 0 neutral · avg impact 7.4/10.
BEARISH15-12G7/10
Centessa Pharmaceuticals filed a Form 15-12G on July 6, 2026, to voluntarily deregister its ordinary
Jul 6, 2026
BULLISHPREM14A9/10
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as
Apr 17, 2026
BULLISHDEFA14A8/10
Centessa Pharmaceuticals is soliciting shareholder approval for its acquisition by Eli Lilly, expect
Apr 13, 2026
BEARISHCLUSTER7/10
Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from C
Mar 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 10, 2026
earnings_calendar
CNTA Q2 2026 Earnings Scheduled — 2026-08-10
Jun 22, 2026
m_and_a
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of m
Jun 2, 2026
ftd
FTD: CNTA — 239,689 shares ($9.6M) failed to deliver
Settlement: 20260602, Price: $39.86, FTD Value: $9,554,003.54, CENTESSA PHARMACEUTICALS PLC S
May 12, 2026
earnings_calendar
CNTA Q1 2026 Earnings Scheduled — 2026-05-12
Apr 17, 2026
short_interest
FTD: CNTA — 39,776 shares ($1.6M) failed to deliver
Settlement: 20260417, Price: $39.53, FTD Value: $1,572,345.28, CENTESSA PHARMACEUTICALS PLC S
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Next FY | $-1.78 | $-2.06–$-1.30 | -14.1% | +6.2% | 1↑ 3↓ | $0.0B | 5 |
| Next Q | $-0.39 | $-0.39–$-0.39 | 4.9% | +11.0% | 2↑ 1↓ | $0.0B | 1 |
| Current Q | $-0.39 | $-0.39–$-0.39 | -2.6% | +8.0% | 2↑ 1↓ | $0.0B | 1 |
| Current FY | $-1.56 | $-1.56–$-1.56 | -6.9% | +0.0% | 1↑ 2↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.390 | — |
| 7d ago | $-0.398 | +0.008 |
| 30d ago | $-0.424 | +0.034 |
| 60d ago | $-0.422 | +0.032 |
| 90d ago | $-0.392 | +0.002 |
Institutional ownership
Which big funds own CNTA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.0B total value (75,039,386 shares) as of 2026-Q1. Top holders: Avoro, ADAGE, Pentwater. Net buying activity: 14 institutions added/increased vs 6 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 11,430,455 | $454.0M | 15.3% | EXIT -100.0% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8,925,010 | $354.5M | 11.9% | EXIT -100.0% |
| Pentwater Capital Management LP | 8,170,000 | $324.5M | 10.9% | EXIT -100.0% |
| FMR LLC | 6,852,047 | $272.2M | 9.1% | EXIT -100.0% |
| Capital World Investors | 4,832,548 | $191.9M | 6.5% | EXIT -100.0% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,809,000 | $191.0M | 6.4% | EXIT -100.0% |
| MORGAN STANLEY | 4,268,353 | $169.5M | 5.7% | EXIT -100.0% |
| JANUS HENDERSON GROUP PLC | 3,492,977 | $138.7M | 4.7% | — |
| RTW INVESTMENTS, LP | 2,054,175 | $81.6M | 2.7% | EXIT -100.0% |
| FEDERATED HERMES, INC. | 2,049,439 | $81.4M | 2.7% | EXIT -100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | EXIT | 598,197 | 0 | -100.0% | $0.00 |
| JPMORGAN CHASE & CO | EXIT | 477,597 | 0 | -100.0% | $0.00 |
| Capital World Investors | EXIT | 4,832,548 | 0 | -100.0% | $0.00 |
| AMERICAN CENTURY COMPANIES INC | EXIT | 687,427 | 0 | -100.0% | $0.00 |
| FMR LLC | EXIT | 6,852,047 | 0 | -100.0% | $0.00 |
| MORGAN STANLEY | EXIT | 4,268,353 | 0 | -100.0% | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | 1,932,406 | 0 | -100.0% | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | 1,144,560 | 0 | -100.0% | $0.00 |
| UBS Group AG | EXIT | 359,939 | 0 | -100.0% | $0.00 |
| D. E. Shaw & Co., Inc. | EXIT | 643,808 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 24, 2026 | Stuckley Carol | Director | D | 208,474 | — | — |
| Jun 24, 2026 | Weinhoff Gregory M | Chief Business Officer | D | 65,925 | — | — |
| Jun 24, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | D | 221,559 | — | — |
| Jun 24, 2026 | ZBAR BRETT I W | Director | D | 64,570 | — | — |
| Jun 24, 2026 | GOYAL ARJUN | Director | D | 462,585 | — | — |
| Jun 24, 2026 | Kulkarni Samarth | Director | D | 208,474 | — | — |
| Jun 24, 2026 | Hukkelhoven Mathias | Director | D | 96,000 | — | — |
| Jun 24, 2026 | Weinhoff Gregory M | Chief Business Officer | D | 584,321 | — | — |
| Jun 24, 2026 | Kanes Stephen | Chief Medical Officer | D | 120,000 | — | — |
| Jun 24, 2026 | De Rubertis Francesco | Director | D | 4,398,519 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CNTA.
Shares short
1,609,679
Settlement Jun 15, 2026
Change vs prior
-37.4%
Semi-monthly cycle
Days to cover
1.2
At avg daily volume
All CNTA filing & press-release reports (5)
- 15-12G reportJul 6, 2026
- PREM14A reportApr 17, 2026
- DEFA14A reportApr 13, 2026
- CLUSTER reportMar 16, 2026
- CLUSTER reportMar 13, 2026